Landscape Capital Management L.L.C. bought a new position in shares of Haemonetics Co. (NYSE:HAE) in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund bought 32,798 shares of the medical instruments supplier’s stock, valued at approximately $3,947,000. Landscape Capital Management L.L.C. owned 0.06% of Haemonetics as of its most recent filing with the SEC.

Several other hedge funds also recently made changes to their positions in the stock. Bridge City Capital LLC boosted its holdings in shares of Haemonetics by 0.5% during the 2nd quarter. Bridge City Capital LLC now owns 31,765 shares of the medical instruments supplier’s stock worth $3,823,000 after buying an additional 156 shares during the period. Retirement Systems of Alabama raised its stake in Haemonetics by 0.3% in the 2nd quarter. Retirement Systems of Alabama now owns 66,603 shares of the medical instruments supplier’s stock worth $8,015,000 after purchasing an additional 205 shares in the last quarter. Alpha Windward LLC acquired a new stake in Haemonetics in the 2nd quarter worth about $29,000. Financial Gravity Wealth Inc. acquired a new position in shares of Haemonetics in the 2nd quarter valued at approximately $40,000. Finally, Arjuna Capital raised its position in shares of Haemonetics by 13.5% in the 2nd quarter. Arjuna Capital now owns 3,415 shares of the medical instruments supplier’s stock valued at $411,000 after buying an additional 405 shares in the last quarter. 98.47% of the stock is owned by institutional investors and hedge funds.

Several equities analysts have recently commented on HAE shares. Barrington Research restated an “outperform” rating and issued a $139.00 target price (up from $116.00) on shares of Haemonetics in a research report on Wednesday, August 7th. Jefferies Financial Group boosted their target price on shares of Haemonetics from $125.00 to $140.00 and gave the company a “buy” rating in a research report on Friday, August 2nd. Raymond James boosted their target price on shares of Haemonetics from $110.00 to $150.00 and gave the company an “outperform” rating in a research report on Wednesday, August 7th. JMP Securities boosted their target price on shares of Haemonetics to $145.00 and gave the company an “outperform” rating in a research report on Wednesday, August 7th. Finally, Morgan Stanley boosted their target price on shares of Haemonetics from $128.00 to $148.00 and gave the company an “overweight” rating in a research report on Wednesday, August 7th. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $140.67.

Shares of NYSE:HAE traded up $0.58 during midday trading on Thursday, hitting $135.38. The stock had a trading volume of 9,334 shares, compared to its average volume of 358,105. The stock has a 50-day moving average price of $123.70. The company has a market capitalization of $6.76 billion, a P/E ratio of 56.64, a P/E/G ratio of 3.26 and a beta of 0.82. The company has a quick ratio of 1.34, a current ratio of 2.10 and a debt-to-equity ratio of 0.54. Haemonetics Co. has a fifty-two week low of $80.24 and a fifty-two week high of $137.49.

Haemonetics (NYSE:HAE) last issued its earnings results on Tuesday, August 6th. The medical instruments supplier reported $0.81 EPS for the quarter, beating the consensus estimate of $0.63 by $0.18. The company had revenue of $238.50 million during the quarter, compared to analysts’ expectations of $236.82 million. Haemonetics had a net margin of 5.05% and a return on equity of 21.07%. The business’s revenue for the quarter was up 4.0% compared to the same quarter last year. During the same period in the previous year, the company earned $0.59 EPS. As a group, equities research analysts expect that Haemonetics Co. will post 3.03 earnings per share for the current fiscal year.

In related news, CEO Christopher Simon sold 24,412 shares of Haemonetics stock in a transaction that occurred on Thursday, May 23rd. The shares were sold at an average price of $99.39, for a total transaction of $2,426,308.68. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, VP Dan Goldstein sold 1,107 shares of Haemonetics stock in a transaction that occurred on Thursday, June 6th. The shares were sold at an average price of $103.25, for a total transaction of $114,297.75. The disclosure for this sale can be found here. Insiders have sold a total of 48,830 shares of company stock worth $5,153,165 over the last ninety days. 1.32% of the stock is currently owned by insiders.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides hematology products and solutions. The company operates through five segments: North America Plasma; Americas Blood Center and Hospital; Europe, Middle East and Africa; Asia Pacific; and Japan. It offers automated plasma collection devices and related disposables, including NexSys PCS plasmapheresis system and PCS2 equipment and disposables, plasma collection containers, and intravenous solutions, as well as information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system.

Further Reading: How a Put Option Works

Want to see what other hedge funds are holding HAE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Haemonetics Co. (NYSE:HAE).

Institutional Ownership by Quarter for Haemonetics (NYSE:HAE)

Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.